Abstracts tagged "Psoriatic arthritis"

Abstract Number: L12 • ACR Convergence 2023
Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
Alan Kivitz¹, Elena Tomaselli Muensterman², Arthur Kavanaugh³, Désirée van der Heijde⁴, Piotr A. Klimiuk⁵, Guillermo Valenzuela⁶, Eva Dokoupilova⁷, Gabrielle Poirier⁸, Bhaskar Srivastava⁸, Sue Dasen⁸, Xinyan Zhang⁸, Mona Trivedi², Haoling Holly Weng⁹, Ting Hong¹⁰, Peter Pothula¹⁰ and Xenofon Baraliakos¹¹, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Division of Rheumatology, Allergy & Immunology, University of California San Diego Medical School, San Diego, CA, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁵Department of Rheumatology and Internal Diseases, Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Białystok, Poland, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University and MEDICAL PLUS, s.r.o., Brno and Uherské Hradiště, Czech Republic, ⁸Nimbus Discovery, Inc., Boston, MA, ⁹HW MedAdvice LLC, San Diego, CA, ¹⁰Takeda Development Center Americas, Inc., Boston, MA, ¹¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis (PsO). TAK-279 is…
Abstract Number: 0483 • ACR Convergence 2023
The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA)
Gary Macfarlane¹, Ovidiu Rotariu², Stephanie Lembke², Flavia Sunzini³, Gareth T. Jones¹ and Neil Basu³, ¹Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²University of Aberdeen, Aberdeen, United Kingdom, ³University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Co-morbid fibromyalgia has been shown to be an important influence on non-response in patients with some inflammatory arthritides. Around 1 in 5 patients with…
Abstract Number: 0499 • ACR Convergence 2023
Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry
Alexis R Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Silky Beaty⁴, Robert Low⁴ and Philip J. Mease⁵, ¹University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Duluth, GA, ³CorEvitas, LLC, Waltham, MA, ⁴UCB Pharma, Smyrna, GA, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Improvement in both joint and skin manifestations is an important goal in the treatment of psoriatic arthritis (PsA). This study describes durability of 50%…
Abstract Number: 0750 • ACR Convergence 2023
Multispectral Optoacoustic Tomography of the Entheses Reveals Common Metabolic and Architectural Tissue Patterns in Psoriasis and Psoriatic Arthritis Independent of Inflammation
Filippo Fagni¹, Koray Tascilar¹, Rita Noversa de Sousa², Sara Bayat¹, Lukas Sollfrank³, Arnd Kleyer⁴, Michael Sticherling⁵, Adrian Regensburger⁶, Ferdinand Knieling⁶, Georg Schett⁷, Maximilian Waldner⁸ and David Simon¹, ¹Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department Dermatology, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴University Hospital Erlangen, Erlangen, Germany, ⁵Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany, ⁶Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Department of Internal Medicine 1, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Multispectral optoacoustic tomography (MSOT) is a novel imaging platform that combines ultrasound (US) with optoacoustic imaging to allow non-invasive in vivo quantification of key…
Abstract Number: 1217 • ACR Convergence 2023
Sex Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey
Lihi Eder¹, Pascal Richette², Laura Coates³, Valderilio Feijó Azevedo⁴, Joseph C. Cappelleri⁵, Megan Hoang⁶, Jade Moser⁷ and Meriem Kessouri⁸, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Lariboisière Hospital, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Department of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Curitiba, Paraná, Brazil, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc., New York, NY, ⁷The Harris Poll, Rochester, NY, ⁸Pfizer Inc., Paris, France
Background/Purpose: Women with PsA have more severe disease activity and lower health-related quality of life vs men.1 This post hoc analysis assessed sex differences in…
Abstract Number: 1422 • ACR Convergence 2023
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data
Kenneth Gordon¹, Andrew Blauvelt², Herve Bachelez³, Laura Coates⁴, Blair Kaplan⁵, Willem Koetse⁵, Leonidas Drogaris⁵, Ranjeeta Sinvhal⁵ and Kim A Papp⁶, ¹Medical College of Wisconsin, Milwaukee, WI, ²Oregon Medical Research Center, Portland, OR, ³APHP Hopital Saint-Louis, Universite de Paris, Paris, France, ⁴University of Oxford, Oxford, United Kingdom, ⁵AbbVie, Inc., North Chicago, IL, ⁶Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada
Background/Purpose: Risankizumab, an interleukin-23 inhibitor, was efficacious and well tolerated in plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinical trials.The objective of this integrated data…
Abstract Number: 1438 • ACR Convergence 2023
Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active PsA
Enrique Soriano¹, Mitsumasa Kishimoto², Emmanouil Rampakakis³, Francois Nantel⁴, May Shawi⁵, Frederic Lavie⁶, Philip J. Mease⁷ and Dafna Gladman⁸, ¹Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Kyorin University School of Medicine, Yokohoma, Japan, ³McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁴Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁷Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Late-onset PsA may be associated with elevated acute phase reactants, higher joint count, and erosive disease at diagnosis1,2. Given potential phenotype differences and increasing…
Abstract Number: 1692 • ACR Convergence 2023
Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)
Romain Aymon¹, Denis Mongin², Burkhard Leeb³, Monika Mustak-Blagusz⁴, Jakub Závada⁵, Karel Pavelka⁶, Dan Nordstrom⁷, Nina Trokovic⁸, Florenzo Iannone⁹, Catalin Codreanu¹⁰, Ziga Rotar¹¹, Tore Kvien¹², Sella Provan¹³, Manuel Enrique Pombo Suarez¹⁴, Fernando Alonso¹⁵, Fatos Onen¹⁶, Nevsun Inanc¹⁷, Louis Coupal¹⁸, Denis Choquette¹⁹, Galina Lukina²⁰, Ori Elkayam²¹, Victoria Furer²¹, Ana Maria Rodrigues²², Delphine COURVOISIER²³, Axel Finckh²⁴, Michael Nissen² and Kim Lauper²⁵, ¹Geneva University Hospitals, Collonges-sous-Salève, France, ²Geneva University Hospitals, Geneva, Switzerland, ³BioReg, Stockerau, Austria, ⁴BioReg, Vienna, Austria, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁷Helsinki University Hospital, Helsinki, Finland, ⁸University of Helsinki, Helsinki, Finland, ⁹Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁰Center for Rheumatic Diseases, Bucharest, Romania, ¹¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹²Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹³Diakonhjemmet Hospital, Oslo, Norway, ¹⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ¹⁵Spanish Society of Rheumatology, Madrid, Spain, ¹⁶Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁷Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁸Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²⁰Federal state budgetary scientific institution "V.A. Nasonova Research Institute of Rheumatology", Moscow, Russia, ²¹Tel Aviv Medical Center, Tel Aviv, Israel, ²²Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ²³Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²⁴HUG, Geneva, Switzerland, ²⁵Geneva University Hospitals, Genève, Switzerland
Background/Purpose: JAK-inhibitors (JAKi) are increasingly being prescribed to treat various inflammatory conditions, including psoriatic arthritis (PsA). While the understanding of JAKi efficacy and safety in…
Abstract Number: 2228 • ACR Convergence 2023
Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment
William R Tillett¹, Laura Coates², marijn vis³, Enrique Soriano⁴, Joseph F. Merola⁵, Miriam Zimmermann⁶, May Shawi⁷, Mohamed Sharaf⁸, Peter Nash⁹ and Philip Helliwell¹⁰, ¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, ⁷Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁸Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁹School of Medicine, Griffith University, Brisbane, Australia, ¹⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19 subunit inhibitor, was shown to reduce mean changes in radiographic progression vs placebo (PBO) by week (W)24 and…
Abstract Number: 2244 • ACR Convergence 2023
Switching Between Biologics and Targeted Synthetic Therapies Due to Inefficacy in Psoriatic Arthritis
Dalifer Freites Núñez¹, Maria Rodriguez Laguna¹, Cristina Hormigos martín¹, zulema Rosales², Leticia Leon³, Gloria Candelas¹, Daniel Rubio⁴, Jose Otazu¹, Benjamin Fernandez¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ⁴Complutense University, Madrid, Spain
Background/Purpose: Biological and targeted synthetic therapies (ts/bDMARDs) have transformed the management ofPsoriatic arthritis (PsA).However, PsA might experience ts/bDMARD failure, (mainly due to inefficacy), and switching…
Abstract Number: 2566 • ACR Convergence 2023
Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database
Léa Bastard¹, pascal claudepierre², Laetitia Penso³, Emilie Sbidian⁴ and Laura PINA VEGAS⁵, ¹Henri Mondor University Hospital (APHP) / Rheumatology Department, Créteil, France, ²Universitary Henri Mondor Hospital, Creteil, France, ³Université Paris Est Créteil, Créteil, France, ⁴Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France, ⁵Henri Mondor University Hospital (APHP), Rheumatology Department, Créteil, France
Background/Purpose: Targeted therapies have demonstrated their efficacy in the treatment of psoriatic arthritis (PsA), with an increased risk of serious infections. However, a comparison of…
Abstract Number: 0484 • ACR Convergence 2023
Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study
Lihi Eder¹, Vinod Chandran², Cheryl Rosen³, Richard J. Cook⁴ and Dafna Gladman⁵, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Division of Dermatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Simple and accessible biomarkers that predict the development of psoriatic arthritis (PsA) among psoriasis patients are critically needed to improve early detection of high-risk…
Abstract Number: 0500 • ACR Convergence 2023
Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention
Jose Federico Diaz-Gonzalez¹, Luis Cea-Calvo², Enrique González-Dávila³, Marta Sánchez-Jareño², Manuel Enrique Pombo Suarez⁴, Fernando Alonso⁵ and Isabel Castrejon⁶, ¹Hospital Universitario de Canarias, La Laguna, Spain, ²Medical Affairs, MSD Spain, Madrid, Spain, ³Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Selecting patients with the highest probability of long-term retention of biological treatments is important from a clinical and cost-effectiveness point of view. In this…
Abstract Number: 0775 • ACR Convergence 2023
Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study
Amy Peeters, C.A.J Michielsens, Elien Mahler, Lise Verhoef, Alfons den Broeder, Nathan den Broeder and Noortje van Herwaarden, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are effective in PsA and axial SpA, but are associated with increased infections risk, patient burden and high costs.…
Abstract Number: 1346 • ACR Convergence 2023
Semen Analysis of Patients with Psoriatic Arthritis, Axial Spondyloarthritis and Healthy Controls
Katya Meridor¹, Shimi Barda², Ofir Elalouf², Victoria Furer², Sara Pel³, Hila Nochomovitz⁴, michael zisapel², Jonathan Wollman², Reut Tzemach², Mark Berman⁵, Sara Borok⁶, Hagit Sarbagil-Maman⁷, Hagit Padova⁸, David levartovsky², Tzippy Shochat⁹, Daphna Paran², Ron Hauser², Ori Elkayam² and Ari Polachek⁶, ¹Tel Aviv Medical Center, Kfar Saba, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Tel Aviv Medical Center, Modiin, Israel, ⁴Ichilov, Tel Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Sourasky Medical Center, Tel Aviv, Israel, ⁷Tel Aviv Sourasky Medical center, Kiryat Ono, Israel, ⁸Tel Aviv Medical center, Petah-Tikva, Israel, ⁹Rabin Medical Center, Modiin, Israel
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are commonly diagnosed in young males in their reproductive years. However, only a few studies have investigated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].